Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Event Logistics

- PMLiVE

Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study

There are currently no treatments that target the underlying cause of C3G or IC-MPGN

- PMLiVE

UCLA launches study of personalised cancer vaccine in paediatric brain tumours

H3 G34-mutant diffuse hemispheric gliomas are brain tumours commonly found in adolescents and young adults

Image of women sitting in a waiting room

Unveiling the truth: A journey into women’s representation in clinical trials

We explore the historical exclusion of women from clinical trials, its consequences on medical research and treatment efficacy and the ongoing efforts to ensure their representation.

Cuttsy + Cuttsy

- PMLiVE

NHS winter planning 2024–25 – Engaging with NHS decision-makers between now and Christmas

How is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months?...

Petauri Evidence

- PMLiVE

Eisai and SEED enter molecular glue degrader partnership worth up to $1.5bn

The companies are aiming to develop candidates for multiple neurodegeneration and oncology targets

- PMLiVE

NHS England announces positive results for type 2 diabetes remission programme

The condition accounts for approximately 90% of all diabetes cases in the UK

Bayer symbol

Bayer shares promising results for Kerendia in phase 3 heart failure study

Approximately 55% of heart failure patients have an LVEF of at least 40%

- PMLiVE

Avoid Costly Clinical Trial Adjustments with Origins – This Simple Solution Will Change Everything!

Low recruitment and retention rates in clinical trials can lead to costly protocol adjustments and trial delays. Visit the Origins Knowledge Centre and watch our latest video to discover how...

Origins – The Patient Focused Specialists

- PMLiVE

Patient Recruitment & Retention Webinar for Influenza Studies

Join the upcoming webinar which will discuss key patient recruitment & retention challenges and solutions for upcoming influenza studies.

Innovative Trials

- PMLiVE

Novartis’ Fabhalta granted FDA approval for rare kidney disease IgA nephropathy

Approximately 25 people per million worldwide are diagnosed with IgAN every year

- PMLiVE

NICE recommends Vertex/CRISPR’s Casgevy gene therapy for beta thalassaemia

An estimated 460 patients in England with severe cases of the blood disorder could be eligible for Casgevy

- PMLiVE

Equillium’s itolizumab shows promise in phase 3 graft versus host disease study

About a third of patients who have undergone a stem cell or bone marrow transplant will develop the condition

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links